Jump to content

Indegene: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Fixed in infobox.
mNo edit summary
Tags: Reverted Visual edit
Line 45: Line 45:
In February 2021, [[the Carlyle Group]] and Brighton Park Capital invested $200 million in Indegene.<ref name="LiveMint">{{cite news | last=Madhurima| first=Nandy| title =Indegene to raise $200 mn from Carlyle, Brighton Park| newspaper =[[LiveMint]]| date =3 February 2021 | url =https://www.livemint.com/companies/start-ups/indegene-to-raise-200-mn-from-carlyle-brighton-park-11612286897793.html| access-date =20 August 2021}}</ref> In August 2021, Indegene acquired Medical Marketing Economics (MME), an American [[market access]] and [[pricing science|pricing strategy]] company, for $10 million.<ref>{{cite news |last1=Baruah |first1=Ayushman |title=Indegene acquires US-based Medical Marketing Economics for $10 mn |url=https://www.livemint.com/companies/news/indegene-acquires-us-based-medical-marketing-economics-for-10-mn-11630322193354.html |access-date=28 April 2024 |work=Mint |date=30 August 2021 |language=en}}</ref>
In February 2021, [[the Carlyle Group]] and Brighton Park Capital invested $200 million in Indegene.<ref name="LiveMint">{{cite news | last=Madhurima| first=Nandy| title =Indegene to raise $200 mn from Carlyle, Brighton Park| newspaper =[[LiveMint]]| date =3 February 2021 | url =https://www.livemint.com/companies/start-ups/indegene-to-raise-200-mn-from-carlyle-brighton-park-11612286897793.html| access-date =20 August 2021}}</ref> In August 2021, Indegene acquired Medical Marketing Economics (MME), an American [[market access]] and [[pricing science|pricing strategy]] company, for $10 million.<ref>{{cite news |last1=Baruah |first1=Ayushman |title=Indegene acquires US-based Medical Marketing Economics for $10 mn |url=https://www.livemint.com/companies/news/indegene-acquires-us-based-medical-marketing-economics-for-10-mn-11630322193354.html |access-date=28 April 2024 |work=Mint |date=30 August 2021 |language=en}}</ref>


Indegene went [[Public company|public]] in May 2024 with an [[initial public offering]], raising {{INRconvert|1842|c}}. It listed on the [[Bombay Stock Exchange|BSE]] and the [[National Stock Exchange of India|NSE]].<ref>{{cite news |last1=Narayanan |first1=KS Badri |title=Indegene IPO opens today in ₹430-452 price band |url=https://www.thehindubusinessline.com/markets/ipo-screener-indegene-issue-opens-today-in-430-452-price-band/article68143174.ece |access-date=6 May 2024 |work=BusinessLine |date=6 May 2024 |language=en}}</ref>
Indegene went [[Public company|public]] in May 2024 with an [[initial public offering]], raising {{INRconvert|1842|c}}. It listed on the [[Bombay Stock Exchange|BSE]] and the [[National Stock Exchange of India|NSE]].<ref>{{cite news |last1=Narayanan |first1=KS Badri |title=Indegene IPO opens today in ₹430-452 price band |url=https://www.thehindubusinessline.com/markets/ipo-screener-indegene-issue-opens-today-in-430-452-price-band/article68143174.ece |access-date=6 May 2024 |work=BusinessLine |date=6 May 2024 |language=en}}</ref><ref>{{Cite web |date=2024-05-10 |title=Indegene IPO - UpcomingIPOTracker |url=https://upcomingipotracker.com/india/indegene-ipo/ |website=UpcomingIPOTracker |language=en-US}}</ref>


==Operations==
==Operations==

Revision as of 11:56, 11 June 2024

Indegene Limited
FormerlyIndegene Lifesystems Private Limited (1998–2016)
Indegene Private Limited (2016–2022)
Company typePublic
Industry
Founded1998; 26 years ago (1998)
FoundersRajesh Nair
Manish Gupta
Sanjay Parikh
Anand Kiran
Gaurav Kapoor
Headquarters
Bangalore
,
India
Area served
Worldwide
Key people
Manish Gupta (CEO)[1]
RevenueIncrease ₹2,589 crore (US$310 million) (FY24)[2]
Increase ₹584 crore (US$70 million) (FY24)[2]
Increase ₹336 crore (US$40 million) (FY24)[2]
Owners
Number of employees
5,081 (March 2024)[2]
Websitewww.indegene.com

Indegene Limited is an Indian company that provides research and commercialization services to biopharmaceutical and healthcare enterprises.[4][5][6] Based in Bangalore, the company specializes in pharmaceutical marketing, clinical trials, pharmacovigilance, medical and regulatory affairs, and health informatics.[7][8]

History

Indegene was founded in 1998 by Dr. Rajesh Nair, Manish Gupta, Gaurav Kapoor, Dr.Sanjay Parikh and Anand Kiran.[9] Indegene's first acquisition was Medsn, a company that provided medical education. Medsn continued to operate under the same name in the United States.[10] In 2008, Medsn officially became known as Indegene Pharmaceutical Solutions in the United States. In 2006, Indegene acquired MedCases, a continuing medical education company based in the United States.[6][11]

In 2009, Indegene signed a master service agreement with six pharmaceutical companies.[5][12] The following year, Indegene acquired Canada-based Aptilon, a multichannel marketing firm, for $4 million.[13] The company subsequently acquired Atlanta-based Total Therapeutic Management in 2014.[14]

In September 2019, Indegene acquired London-based consulting company, DT Associates, for $10 million.[15]

In February 2021, the Carlyle Group and Brighton Park Capital invested $200 million in Indegene.[16] In August 2021, Indegene acquired Medical Marketing Economics (MME), an American market access and pricing strategy company, for $10 million.[17]

Indegene went public in May 2024 with an initial public offering, raising ₹1,842 crore (US$220 million). It listed on the BSE and the NSE.[18][19]

Operations

Indegene has offices in India, the United States, the European Union, and Asia-Pacific.[20][11]

In 2011 and 2012, The Economic Times named Indegene one of the best companies to work for in the Professional Services industry.[21]

See also

References

  1. ^ "Indegene on the prowl for global acquisitions". The Hindu Businessline. 12 August 2020. Retrieved 8 January 2023.
  2. ^ a b c d "Fact Sheet – Q4 FY2024" (PDF). Indegene. Retrieved 30 May 2024.
  3. ^ "PE firms Carlyle, Nadathur Fareast, Brighton Park Capital-backed Indegene IPO to open on May 6". Moneycontrol. Retrieved 28 April 2024.
  4. ^ Das, Avik (2 September 2015). "Flipkart, Practo CEOs get top rating from staff". The Economic Times. Retrieved 2 October 2015.
  5. ^ a b Singh, Seema (7 May 2009). "Cutting pharma costs by intelligent marketing". Mint. Retrieved 2 October 2015.
  6. ^ a b Unnikrishnan, CH (8 November 2006). "Indegene buys US firm". Business Standard. Retrieved 2 October 2015.
  7. ^ Murayama, Keiichi (19 February 2015). "India's tech muscle has the world's attention". The Nikkei. Retrieved 2 October 2015.
  8. ^ "Indegene files papers with Sebi; eyes ₹3,200 crore via IPO". mint. 15 December 2022. Retrieved 8 January 2023.
  9. ^ Amirapu, Deepika (9 March 2012). "Indegene eyes US call centre buy for $10–15 million". The Economic Times. Retrieved 2 October 2015.
  10. ^ D'Silva, Jeetha (17 September 2005). "Indegene acquires US medical education co". The Economic Times. Retrieved 2 October 2015.
  11. ^ a b "Indegene acquires MedCases, LLC". NFV Zone. 30 November 2006. Retrieved 2 October 2015.
  12. ^ "Indegene highlights benefits of patient adherence programs for pharma cos". PharmaBiz. 3 June 2011. Retrieved 2 October 2015.
  13. ^ Mukherjee, Rupali (7 November 2012). "Indegene to acquire Canada-based company for $4 million". Times of India. Retrieved 2 October 2015.
  14. ^ Craig, Tara (9 January 2014). "Indegene acquires Total Therapeutic Management". PMLive.com. Retrieved 2 October 2015.
  15. ^ Balakrishnan, Reghu (3 September 2019). "Healthcare tech firm Indegene acquires DT Associates". The Economic Times. Retrieved 28 April 2024.
  16. ^ Madhurima, Nandy (3 February 2021). "Indegene to raise $200 mn from Carlyle, Brighton Park". LiveMint. Retrieved 20 August 2021.
  17. ^ Baruah, Ayushman (30 August 2021). "Indegene acquires US-based Medical Marketing Economics for $10 mn". Mint. Retrieved 28 April 2024.
  18. ^ Narayanan, KS Badri (6 May 2024). "Indegene IPO opens today in ₹430-452 price band". BusinessLine. Retrieved 6 May 2024.
  19. ^ "Indegene IPO - UpcomingIPOTracker". UpcomingIPOTracker. 10 May 2024.
  20. ^ Vijay, Nandita (7 November 2012). "Indegene plans next phase of growth through acquisition in US, EU markets". PharmaBiz. Retrieved 2 October 2015.
  21. ^ "Best companies to work for 2012: Companies that came up trumps across various sectors". The Economic Times. 16 July 2012. Retrieved 2 October 2015.
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Indegene&oldid=1228469637"